1 - 1 / 1 1 |
1. Multiple switches from the originator infliximab to biosimilars is effective and safe in inflammatory bowel disease Jurij Hanžel, Jeroen M. Jansen, Rinze W. F. ter Steege, Krisztina B. Gecse, Geert R. D'Haens, 2022, original scientific article Keywords: SB2, CT-P13, multiple switches, Crohn's disease, inflammatory bowel disease, ulcerative colitis, adults, feces, c-reactive protein, infliximab, adverse event, leukocyte l1 antigen complex, infusion procedures, biosimilar pharmaceuticals, disease remission, imputation, antidrug antibody, infliximab-dyyb |